Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes

Archives of Pharmacal Research

Volumn 33, Issue 11, 2010, Pages 1825-1833

  Won, Tae Joon ^a   Jung, Yu Jin ^a   Kwon, Seok Joong ^a   Lee, Yoon Jeong ^a   Lee, Do Ik ^a   Min, Hyeyoung ^a   Park, Eon Sub ^a   Joo, Seong Soo ^b   Hwang, Kwang Woo ^a  

^a Chung Ang University   (South Korea)

^b Gangneung Wonju National University   (South Korea)

Author keywords

Autoimmune IDDM; Programmed death ligand 1; Programmed death ligand 2; Programmed death 1; T cell activation

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; INTERLEUKIN 2; PROGRAMMED DEATH 1 LIGAND 1; STREPTOZOCIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE EXPRESSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GENE EXPRESSION; IMMUNE TOLERANCE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDES; T-LYMPHOCYTES;

EID: 78751501414     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-1115-3     Document Type: Article

References (29)

1. Almawi, W. Y., Tamim, H., and Azar, S. T., Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J. Clin. Endocrinol. Metab., 84, 1497-1502 (1999).
2. Alonso, N., Soldevila, B., Sanmarti, A., Pujol-Borrell, R., and Martinez-Caceres, E., Regulatory T cells in diabetes and gastritis. Autoimmun. Rev., 8, 659-662 (2009).
3. Bala, K. K. and Moudgil, K. D., Induction and maintenance of self tolerance: the role of CD4+CD25+ regulatory T cells. Arch. Immunol. Ther. Exp. (Warsz.), 54, 307-321 (2006).
4. Brazil, D. P., Yang, Z. Z., and Hemmings, B. A., Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci., 29, 233-242 (2004).
5. Cantor, J. and Haskins, K., Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 dia-betes: evidence for involvement of CCR8 and CCL1. J. Immunol., 179, 5760-5767 (2007).
6. Cardozo, A. K, Proost, P., Gysemans, C, Chen, M. C, Mathieu, C, and Eizirik, D. L., IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia, 46, 255-266 (2003).
7. Chen, L., Hussien, Y., Hwang, K. W., Wang, Y., Zhou, P., and Alegre, M. L., Overexpression of program death-1 in T cells has mild impact on allograft survival. Transpl. Int., 21, 21-29 (2008).
8. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C, Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., and Honjo, T., Engagement of the PD-1 immunoinhibi-tory receptor by a novel B7 family member leads to nega-tive regulation of lymphocyte activation. J. Exp. Med., 192, 1027-1034 (2000).
9. Greenwald, R. J., Freeman, G. J., and Sharpe, A. H., The B7 family revisited. Annu. Rev. Immunol., 23, 515-548 (2005).
10. Kane, L. P., Shapiro, V. S., Stokoe, D., and Weiss, A., Induction of NF-kappaB by the Akt/PKB kinase. Curr. Biol., 9, 601-604 (1999).
11. Keir, M. E., Francisco, L. M., and Sharpe, A. H., PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol., 19, 309-314 (2007).
12. Knip, M. and Siljander, H., Autoimmune mechanisms in type 1 diabetes. Autoimmun. Rev., 7, 550-557 (2008).
13. Kwon, N. S, Lee, S. H, Choi, C S, Kho, T, and Lee, H. S., Nitric oxide generation from streptozotocin. FASEB J., 8, 529-533 (1994).
14. Lal, G. and Bromberg, J. S., Epigenetic mechanisms of regulation of Foxp3 expression. Blood, 114, 3727-3735 (2009).
15. Loke, P. and Allison, J. P., PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. U.S.A., 100, 5336-5341 (2003).
16. Madrid, L. V., Mayo, M. W., Reuther, J. Y., and Baldwin, A. S., Jr., Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem., 276, 18934-18940 (2001).
17. Mellanby, R. J., Thomas, D., Phillips, J. M., and Cooke, A., Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology, 121, 15-28 (2007).
18. Okazaki, T. and Honjo, T., The PD-1-PD-L pathway in immunological tolerance. Trends Immunol., 27, 195-201 (2006).
19. Okazaki, T. and Honjo, T., PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol., 19, 813-824 (2007).
20. Parry, R. V., Riley, J. L., and Ward, S. G., Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. Trends Immunol., 28, 161-168 (2007).
21. Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., and Bluestone, J. A., B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune dia-betes. Immunity, 12, 431-440 (2000).
22. Sgouroudis, E. and Piccirillo, C. A., Control of type 1 diabetes by CD4+Foxp3+ regulatory T cells: lessons from mouse models and implications for human disease. Diabetes Metab. Res. Rev., 25, 208-218 (2009).
23. Tang, Q., Henriksen, K J., Boden, E. K, Tooley, A. J., Ye, J., Subudhi, S. K., Zheng, X. X., Strom, T. B., and Bluestone, J. A., Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol., 171, 3348-3352 (2003).
24. Tang, Q. and Bluestone, J. A., Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev., 212, 217-237 (2006).
25. Tang, Q., Adams, J. Y., Tooley, A. J., Bi, M., Fife, B. T., Serra, P., Santamaria, P., Locksley, R. M., Krummel, M. F., and Bluestone, J. A., Visualizing regulatory T cell con-trol of autoimmune responses in nonobese diabetic mice. Nat Immunol., 7, 83-92 (2006).
26. Thorvaldson, L., Johansson, S. E., Hoglund, P., and Sandler, S., Impact of plastic adhesion in vitro on analysis of Th1 and Th2 cytokines and immune cell distribution from mice with multiple low-dose streptozotocin-induced dia-betes. J. Immunol. Methods, 307, 73-81 (2005).
27. Wang, C. J, Chou, F. C, Chu, C. H, Wu, J. C, Lin, S. H-Chang, D. M., and Sytwu, H. K., Protective role of pro grammed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models. Diabetes, 57, 1861-1869 (2008).
28. Yoon, J. W., Jun, H. S., and Santamaria, P., Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity, 27, 109-122 (1998).
29. Yoshida, T., Jiang, F., Honjo, T., and Okazaki, T., PD-1 defi-ciency reveals various tissue-specific autoimmunity by H-2b and dose-dependent requirement of H-2g7 for diabetes in NOD mice. Proc. Natl. Acad. Sci. U.S.A., 105, 3533-3538 (2008).